DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01628445

SAIL

TerminatedPhase 3

Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

Phase 3 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

52

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≤45•HbA1c 7.5-10.5%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01628445
Org study IDU1111-1126-3937

Timeline

Milestones

Study first posted2012-06-26estimated
Last update posted2016-01-21estimated
Study start2012-08 (month precision)
Primary completion2015-11actual (month precision)
Study completion2015-11actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes
•BMI≤45 kg/m2
•A1c ≥7.5% and ≤10.5%

Exclusion criteria

•type 1 diabetes
•symptoms of poorly controlled diabetes
•eGFR <50 ml/min/1.73m2

Endpoints (13)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Cardiometabolic biomarkers
4
Weight & body composition
2
Safety / tolerability / PK
2
Patient-reported / QoL
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

Change in waist circumference

Time frame:Baseline and 24 weeks

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change in body weight

Time frame:Baseline and 24 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

Change in A1c

Time frame:Baseline to 24 wks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of patients achieving A1C < or equal to 7%

Time frame:Baseline and 24 weeks

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in fasting blood glucose

Time frame:Baseline adn 24 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Postprandial glucose reduction through measurement of 7 point glucose profile

Time frame:Baseline, 4 weeks, 12 weeks and 24 weeks

Postprandial glucose

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints
Secondary/protocol endpoint

Change in Systolic Blood pressure

Time frame:Baseline and 24 weeks

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in diastolic blood pressure

Time frame:Baseline and 24 weeks

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in heart rate

Time frame:Baseline and 24 weeks

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in lipid profile

Time frame:Baseline and 24 weeks

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Diabetes Treatment Satisfaction

Time frame:Baseline, 12 weeks and 24 weeks

change from baseline, improvement

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

Percentage of patients experiencing hypoglycemia

Time frame:Baseline and 24 weeks

Documented hypoglycemia

threshold achievement, event

Secondary/protocol endpoint

Occurence of undetected hypoglycemia as measured by continuous glucose monitoring

Time frame:Baseline, 12 weeks and 24 weeks

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.